Thitinun RaknooCollege of Pharmacotherapy, Thailand
Title: Incidence, risk and risk factors for acute kidney injury associated with the use of intravenous indomethacin in neonatal patent ductus arteriosus: A 16-year retrospective cohort study
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV 2) is a strain of coronavirus that causes coronavirus disease 2019 (COVID-19). The COVID-19 pandemic from human-to-human transmission. A small percentage of children have severe infections. Pediatrics generally represents an asymptomatic infection. Intravenous remdesivir has been used in pediatrics to treat severe COVID-19, but results and studies on mortality rates are still lacking. While the rate of dispensing intravenous remdesivir has increased, awareness and knowledge of drug use are conflicted, and there are few studies among healthcare providers. We performed a case series study on pediatrics hospitalized in a tertiary care hospital treated with intravenous remdesivir regarding the usage of remdesivir, safety profile, clinical outcomes, and adverse drug reactions. We performed a case series study on pediatrics hospitalized in a tertiary care hospital treated with intravenous remdesivir regarding the usage of remdesivir, safety profile, clinical outcomes, and adverse drug reactions.
Thitinun Raknoo graduated from the Faculty of Pharmacy, Silpakorn University, Thailand. She completed her Board Certified Pharmacotherapy in 2022 and a specialized fellowship in Pediatric Pharmacotherapy. Thitinun is a pediatric clinical pharmacist. She usually works in hospitals, providing proper medication to pediatric patients. She works with doctors and a multidisciplinary team to ensure that the special needs of pediatric medicine are met. In addition, she participates in the Pharmacy Council of Thailand and the College of Pharmacotherapy of Thailand (C.Ph.T.)